A small preliminary study showed that adding pioglitazone to imatinib therapy might have a favorable impact on residual disease in chronic myeloid leukemia, as measured by conversion to molecular response 4.5.
Many patients with stable CML may be able to safely decrease their dose of tyrosine kinase inhibitor to half of the standard dose and improve TKI-related side effects, according to the results of the DESTINY trial.
According to a long-term follow-up analysis of a phase I/II trial, bosutinib provides durable responses and a favorable toxicity profile in patients with chronic phase CML who are resistant/intolerant to other tyrosine kinase inhibitors.
Expression levels of CD62L and related immunologic markers are correlated with treatment responses and outcome in patients with CML, according to a new analysis. The markers could have prognostic value if validated in other cohorts.